Revvity, Inc.
RVTY Healthcare Medical - Diagnostics & Research NYSE
$91.34
$-5.23 (-5.42%)
Open: $94.29 | High: $95.24 | Low: $90.90 | Prev Close: $96.57
Market Cap: $10.36B
Volume: 1.2M | Avg: 1.4M
Last updated: March 09, 2026 at 02:04 AMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 459
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 44.34 |
| P/B Ratio | 1.43 |
| P/S Ratio | 3.63 |
| EPS | $2.06 |
| Beta | 1.11 |
| Shares Outstanding | 113.38M |
| 52-Week High | $120.39 |
| 52-Week Low | $81.36 |
| SMA 50 | $102.90 |
| SMA 200 | $95.69 |
| Dividend Yield | 0.31% |
| Annual Dividend | $0.28 |
| Next Earnings | April 27, 2026 12:30 PM ET |
Financial Ratios
| Gross Margin | 50.2% |
| Operating Margin | 13.0% |
| Net Margin | 8.5% |
| ROE | 3.2% |
| ROA | 2.0% |
| Debt/Equity | 0.48 |
| Current Ratio | 1.68 |
| Quick Ratio | 1.40 |
Balance Sheet
| Total Assets | $12.17B |
| Total Liabilities | $4.92B |
| Total Equity | $7.25B |
|
|
|
| Cash | $919.87M |
| Total Debt | $3.52B |
| Net Debt | $2.60B |
Income Statement
| Revenue | $2.86B |
| Gross Profit | $1.52B |
| Operating Income | $356.63M |
| Net Income | $241.68M |
|
|
|
| EBITDA | $662.72M |
| Revenue/Share | $25.23 |
Cash Flow
| Operating CF | $581.78M |
| CapEx | $73.52M |
| Free Cash Flow | $508.25M |
|
|
|
| Book Value/Share | $64.04 |
| Tangible Book/Share | $-15.11 |
| Equity/Share | $64.04 |
Technical Indicators
| RSI (14) | 43.03 Neutral |
| MACD |
-2.47
Signal: -2.37
|
| Volatility | 41.10% |
| Trading Signal | Bearish |
Performance & Returns
| 1 Year | -3.14% |
| Sharpe Ratio | 0.03 Fair |
| Volatility (Ann.) | 37.11% Moderate |
| RVTY (1Y) | -3.14% |
| S&P 500 (1Y) | +13.03% |
| Alpha (Excess Return) | -16.17% |
Sector Comparison (Healthcare)
| Metric | RVTY | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 44.34 | 27.34 | 85% |
| P/B Ratio | 1.43 | -19.55 | 19% |
| ROE (%) | 3.24% | -9.35% | 21% |
| Net Margin (%) | 8.46% | 9.33% | 36% |
| Stock Score | 459 | 545.0 | 17% |
| 1Y Return (%) | -3.14 % | +8.36 % | 37% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RVTY | $91.34 | $95.16 | $95.70 | $96.64 | $102.83 | $95.68 | 43.03 | -2.47 | 41.10% | 310198 | Strong Short | Bearish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the RVTY stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| RVTY | Revvity, Inc. (RVTY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript | Neutral | seekingalpha.com | Read More |
| RVTY | Why Is Revvity (RVTY) Down 5.1% Since Last Earnings Report? | Neutral | zacks.com | Read More |
| RVTY | Here's Why You Should Retain Revvity Stock in Your Portfolio for Now | Neutral | zacks.com | Read More |
| RVTY | Revvity, Inc. (RVTY) Presents at TD Cowen 46th Annual Health Care Conference Transcript | Neutral | seekingalpha.com | Read More |
| RVTY | Revvity, Inc. (RVTY) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript | Neutral | seekingalpha.com | Read More |
Recent Insider Trading
No recent insider trading data available for RVTY
Company Information
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
| CEO | Prahlad R. Singh |
| Employees | 11000 |
| Country | US |
| IPO Date | 1965-07-06 |
| Exchange | NYSE |
| Website | https://www.perkinelmer.com |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |
Similar Stocks (Healthcare - Medical - Diagnostics & Research)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category